# Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

> **NCT02691780** · NA · WITHDRAWN · sponsor: **Samsung Medical Center**

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02691780
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12-23
- **Primary completion:** 2018-12
- **Final completion:** 2019-11-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** not enrolled
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02691780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02691780, "Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02691780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*